Which of the following has the highest risk of metabolic syndrome?

A. Haloperidol (Haldol) is a first-generation (typical) antipsychotic, which has a higher risk of extrapyramidal symptoms (EPS) but a lower risk of metabolic syndrome compared to second-generation antipsychotics. B. Aripiprazole (Abilify) is a second-generation (atypical) antipsychotic with a lower risk of metabolic side effects. It has a partial dopamine agonist mechanism, which makes it less likely to cause weight gain, dyslipidemia, or glucose intolerance. C. Clozapine (Clozaril) has the highest risk of metabolic syndrome among antipsychotics. It is associated with significant weight gain, hyperglycemia, dyslipidemia, and an increased risk of diabetes. Regular metabolic monitoring (weight, blood glucose, lipids) is essential for patients taking clozapine. D. Lurasidone (Latuda) is a second-generation antipsychotic with a lower metabolic risk compared to other atypical antipsychotics. It is generally considered weight-neutral and has minimal effects on glucose and lipid metabolism.